The ARWR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARWR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARWR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARWR Detailed Price Forecast - CNN Money||View ARWR Detailed Summary - Google Finance|
|View ARWR Detailed Summary - Yahoo! Finance||View ARWR Stock Research & Analysis - Zacks.com|
|View ARWR Trends & Analysis - Trade-Ideas||View ARWR Major Holders - Barrons|
|View ARWR Call Transcripts - NASDAQ||View ARWR Breaking News & Analysis - Seeking Alpha|
|View ARWR Annual Report - CompanySpotlight.com||View ARWR OTC Short Report - OTCShortReport.com|
|View ARWR Fundamentals - TradeKing||View ARWR SEC Filings - Bar Chart|
|View Historical Prices for ARWR - The WSJ||View Performance/Total Return for ARWR - Morningstar|
|View the Analyst Estimates for ARWR - MarketWatch||View the Earnings History for ARWR - CNBC|
|View the ARWR Earnings - StockMarketWatch||View ARWR Buy or Sell Recommendations - MacroAxis|
|View the ARWR Bullish Patterns - American Bulls||View ARWR Short Pain Metrics - ShortPainBot.com|
|View ARWR Stock Mentions - StockTwits||View ARWR Stock Mentions - PennyStockTweets|
|View ARWR Stock Mentions - Twitter||View ARWR Investment Forum News - Investor Hub|
|View ARWR Stock Mentions - Yahoo! Message Board||View ARWR Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARWR - SECform4.com||View Insider Transactions for ARWR - Insider Cow|
|View ARWR Major Holdings Summary - CNBC||View Insider Disclosure for ARWR - OTC Markets|
|View Insider Transactions for ARWR - Yahoo! Finance||View Institutional Holdings for ARWR - NASDAQ|
|View ARWR Stock Insight & Charts - FinViz.com||View ARWR Investment Charts - StockCharts.com|
|View ARWR Stock Overview & Charts - BarChart||View ARWR User Generated Charts - Trading View|
Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals
Posted on Monday May 21, 2018
NEW YORK, NY / ACCESSWIRE / May 21, 2018 / Agile Therapeutics shares fell hard on Friday after traders pondered the future of the company's Twirla contraceptive Patch. The FDA had a concerning assessment on the patch and has already turned it down twice. Shares of Arrowhead Pharmaceuticals were gaining higher in Friday trading despite any particular news.
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
Posted on Monday May 21, 2018
Arrowhead Pharmaceuticals, Inc. (ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International Conference in San Diego, CA. ARO-ENaC is the first product candidate to leverage the Targeted RNAi Molecule (TRiM™) platform targeting the pulmonary epithelium to address diseases of the lung. ARO-ENaC is an inhaled RNA interference (RNAi) therapeutic targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of CF, a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas.
Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT
Posted on Tuesday May 15, 2018
Q2 2018 Arrowhead Pharmaceuticals Inc Earnings Call
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARWR as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine– Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018.